U.s. fda accepts karyopharm's supplemental new drug application for xpovio as treatment for patients with multiple myeloma after at least one prior line of therapy

U.s. food and drug administration accepts karyopharm’s supplemental new drug application for xpovio® (selinexor) as a treatment for patients with multiple myeloma after at least one prior line of therapy.karyopharm therapeutics - expects decision from fda regarding snda before end of q1 of 2021.
KPTI Ratings Summary
KPTI Quant Ranking